Vasculitis: Clinical Trials

23 trials for Vasculitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 recruiting, 4 not yet recruiting, 3 completed, 3 unknown. 23 Early Phase 1.

By phase and status

PhaseTrialsStatus
Early Phase 123Recruiting 7, Not yet recruiting 4, Completed 3, Unknown 3, Terminated 2, Withdrawn 2, Active not recruiting 1, Suspended 1

Follow Vasculitis: new trials by email Literature Review of Vasculitis trials Research Report on Vasculitis

Trials (filtered) newest first · largest first

All 23 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
CD19-targeted iNKT Cell Injection - IgA Nephropathy (IgAN), Membranous Nephropathy
Early Phase 1Not yet recruitingGrit Biotechnology302027-08-012026-09-11
CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases
RD06-05 CAR-T Cell Injection - SLE - Systemic Lupus Erythematosus, Systemic Sclerosis
Early Phase 1Not yet recruitingNanjing Bioheng Biotech Co., Ltd.302026-09-012026-07-16
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
UCAR T-cell - Autoimmune Diseases, Systemic Lupus Erthematosus (SLE)
Early Phase 1RecruitingThe Children's Hospital of Zhejiang University School of Medicine152026-04-012026-04-02
MTS109 in Patients With Refractory Autoimmune Diseases
MTS109 - Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies
Early Phase 1RecruitingShanghai Changzheng Hospital152026-03-242026-06-30
Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
anti-CD19/BCMA U CAR T cells - Autoimmune Diseases, Systemic Lupus Erythematosus
Early Phase 1RecruitingChanghai Hospital602026-02-202026-02-25
Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases
BCT301 - System Lupus Erythematosus, Systemic Sclerosis (SSc)
Early Phase 1RecruitingPeking University Third Hospital102025-12-112026-09-23
the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases
V001-BCMA - Recurrent or Refractory Systemic Lupus Erythematosus, Recurrent or Refractory IgG4 Related Diseases
Early Phase 1Active not recruitingTongji Hospital452025-11-042026-09-17
A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
RD06-05 CART Cell Injection - SLE, LN
Early Phase 1RecruitingNanjing Bioheng Biotech Co., Ltd.962025-07-242026-08-03
A Study of LCAR-AIO in Subjects With Relapsed/Refractory Autoimmune Diseases
LCAR-AIO T cells - Relapsed/Refractory Autoimmune Diseases
Early Phase 1WithdrawnNanjing Legend Biotech Co.2025-06-172025-07-08
Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV
RD06-04 Cell Injection Infusion - Idiopathic Inflammatory Myopathies, ANCA-Associated Vasculitis
Early Phase 1Not yet recruitingPeking University People's Hospital122025-06-142025-05-22
Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases
RD06-05 CART Cell Injection - SLE, Systemic Sclerosis
Early Phase 1RecruitingNanjing Bioheng Biotech Co., Ltd.182025-01-032026-02-02
Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
CD19 or CD19-BCMA CAR-T - SLE (Systemic Lupus), Systemic Sclerosis
Early Phase 1RecruitingNanjing Bioheng Biotech Co., Ltd.202024-09-142026-03-06
Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases
RD06-04 CART Cell Injection - Systemic Lupus Erythematosus, Systemic Sclerosis
Early Phase 1SuspendedNanjing Bioheng Biotech Co., Ltd.122024-09-132026-02-03
A Study of RD06-04 in Patients With Active Autoimmune Diseases
RD06-04 cell infusion - SLE, Sclerosis
Early Phase 1WithdrawnNanjing Bioheng Biotech Co., Ltd.2024-08-312026-02-03
IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy
IMPT-514 CART Cell Injection - Systemic Lupus Erythematosus (SLE), ANCA Associated Vasculitis (AAV)
Early Phase 1TerminatedThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School32024-06-132026-01-28
The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases
anti-CD19-CAR-T cells - Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome
Early Phase 1Not yet recruitingFirst Affiliated Hospital of Wenzhou Medical University92024-05-272024-05-17
Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers
Meperizumab injection, NUCALA® - Granulomatosis With Polyangiitis, Hemophagocytic Syndrome
Early Phase 1UnknownChia Tai Tianqing Pharmaceutical Group Co., Ltd.882022-06-012022-04-29
A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis
CD19/BCMA CAR T-cells - POEMS Syndrome, Amyloidosis
Early Phase 1UnknownZhejiang University752021-10-082022-03-03
Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease
Atorvastatin and anakinra - Kawasaki Disease
Early Phase 1CompletedUniversity of California, San Diego52019-06-222026-02-25
Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome
HPC cell infusion - Churg-Strauss Syndrome
Early Phase 1TerminatedMounzer Agha12016-04-012017-08-01

Showing 20 of 23. Sign in to see all of them.

Narrower conditions

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (16)  ·  Lupus Erythematosus, Systemic (11)  ·  Scleroderma, Systemic (11)  ·  Myositis (9)  ·  Autoimmune Diseases (7)  ·  Sjogren's Syndrome (6)  ·  Glomerulonephritis, IGA (3)  ·  Antiphospholipid Syndrome (2)  ·  Arthritis, Rheumatoid (2)  ·  Recurrence (2)  ·  Amyloidosis (1)  ·  Anemia, Hemolytic, Autoimmune (1)  ·  Anti-Glomerular Basement Membrane Disease (1)  ·  Behcet Syndrome (1)  ·  Churg-Strauss Syndrome (1)

Broader conditions

Cardiovascular Diseases (23)  ·  Vascular Diseases (23)  ·  Skin Diseases (22)  ·  Skin Diseases, Vascular (22)  ·  Skin and Connective Tissue Diseases (22)  ·  Immune System Diseases (21)  ·  Systemic Vasculitis (18)  ·  Autoimmune Diseases (14)  ·  Connective Tissue Diseases (13)  ·  Musculoskeletal Diseases (12)  ·  Nervous System Diseases (12)  ·  Neuromuscular Diseases (10)  ·  Muscular Diseases (9)  ·  Arthritis (8)

Interventions

Abatacept (1)  ·  Antigens, CD19 (1)  ·  Atorvastatin (1)  ·  Interleukin 1 Receptor Antagonist Protein (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  mepolizumab (1)

Sponsors

Nanjing Bioheng Biotech Co., Ltd. (6)  ·  Changhai Hospital (1)  ·  Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1)  ·  First Affiliated Hospital of Wenzhou Medical University (1)  ·  Grit Biotechnology (1)  ·  Jonsson Comprehensive Cancer Center (1)  ·  Mounzer Agha (1)  ·  NYU Langone Health (1)  ·  Nanjing Legend Biotech Co. (1)  ·  Peking University People's Hospital (1)  ·  Peking University Third Hospital (1)  ·  Shaare Zedek Medical Center (1)  ·  Shanghai Changzheng Hospital (1)  ·  The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1)  ·  The Children's Hospital of Zhejiang University School of Medicine (1)

Countries

China (18)  ·  United States (3)  ·  Israel (1)

Top investigators

Adriana Tremoulet, MD (1)  ·  David Shemesh, MD (1)  ·  He Huang, PhD (1)  ·  LI Sun, Master's (1)  ·  Martin Allen-Auerbach (1)  ·  Mounzer Agha, MD (1)  ·  Qiong Fu, Doctor (1)

NIH funding

R01HL140898 (1)